Provider: View Press Release
Type: Link
Title: FDA grants accelerated approval for GSK’s JEMPERLI (dostarlimab-gxly) for women with recurrent or advanced dMMR endometrial cancer | GSK
Description: FDA grants accelerated approval for GSK’s JEMPERLI (dostarlimab-gxly) for women with recurrent or advanced dMMR endometrial cancer
Provider: View Press Release
Type: Link
Title: GSK and Vir Biotechnology announce EMA review of dual-action monoclonal antibody VIR-7831 for the early treatment of COVID-19 | GSK
Description: GSK and Vir continue discussions with global regulators to make VIR-7831 available to patients with COVID-19.
Provider: View Press Release
Type: Link
Title: GSK provides update on feladilimab, an investigational inducible T cell co-stimulatory (ICOS) agonist | GSK
Description: GSK provides update on feladilimab, an investigational inducible T cell co-stimulatory (ICOS) agonist
Provider: View Press Release
Type: Link
Title: GSK announces Dr Anne Beal to join the Board as Non-Executive Director | GSK
Description: GlaxoSmithKline plc (LSE/NYSE: GSK) today announces that Dr Anne Beal will join the Board of the Company as a Non-Executive Director.
Provider: View Press Release
Type: Link
Title: GSK to support manufacture of Novavax’ COVID-19 vaccine | GSK
Description: GSK to support manufacture of up to 60 million doses of Novavax’ COVID-19 vaccine.
Provider: View Press Release
Type: Link
Title: Lilly, Vir Biotechnology and GSK announce positive topline data from the phase 2 BLAZE-4 trial evaluating bamlanivimab with VIR-7831 in low-risk adults with COVID-19 | GSK
Description: In combination, the 2 monoclonal antibodies demonstrated 70% relative reduction in persistent high viral load at day 7 compared to placebo.